Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + Obinutuzumab in Untreated Mantle Cell Lymphoma
NCT03311126Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Sep 2017
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in mantle cell lymphoma (MCL), sponsored by University of Wisconsin–Madison. Started Sep 2017; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03311126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311126.